Drugs / Bimatoprost
Bimatoprost
also known as
Lumigan · "Lumigan" is the branded name of bimatoprost in eye drop form · Bimatoprost SR · Durysta · T4032 · AGN 192024 · BIM · Bimatoprost 0.03% solution (Lumigan) · +13 more
Other / unclassified targets PTGFR via activation
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | LATISSE | — | 2014-09-04 | fda.gov ↗ |
| Label expansion | US (FDA) | LUMIGAN | — | 2006-06-22 | fda.gov ↗ |
| Approved | EU (EMA) | Lumigan | — | 2002-03-08 | europa.eu ↗ |
| Approved | US (FDA) | LUMIGAN | — | 2001-03-16 | fda.gov ↗ |
Trials 102 · started per year
today
US approved 2001
EU approved 2002
3
1
1
1
3
2
4
6
8
15
3
6
6
8
8
1
3
3
1
5
2
3
2
3
2001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT04738149 | Nov 2021 → May 2022 | vitiligo | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 0 | NCT03708627 | Nov 2017 → Jul 2029 expected | disease of orbital part of eye adnexa | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 0 | NCT02830776 | Nov 2016 → Apr 2017 | eyelid disorder | Tulane University | Completed | No outcome recorded |
| Phase 16 trials | ||||||
| Phase 1 | NCT07641296 | Jul 2026 → Feb 2027 expected | glaucoma, ocular hypertension | SpyGlass Pharma, Inc. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05729594 | Feb → Apr 2023 | — | Laboratoires Thea | Completed | No outcome recorded |
| Phase 1 | NCT02848300 | Jul → Oct 2016 | androgenetic alopecia | Allergan | Completed | No outcome recorded |
| Phase 1 | NCT02676310 | Mar 2016 → Jan 2017 | androgenetic alopecia | Allergan | Terminated | No outcome recorded |
| Phase 1 | NCT02444767 | Mar → Apr 2015 | — | ForSight Vision5, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01189279 | Oct 2010 → Jan 2011 | baldness, male pattern | Allergan | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT06120842 | Oct 2023 → Jan 2025 overdue | cataract, glaucoma, ocular hypertension | SpyGlass Pharma, Inc. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05600673 | Jan 2019 → Jan 2021 | alopecia areata | Ahmed Hassan Nouh MD | Completed | No outcome recorded |
| Phase 1/2 | NCT02742649 | Apr → Dec 2016 | ocular hypertension, open-angle glaucoma | ForSight Vision5, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01157364 | Sep 2010 → Jul 2016 | ocular hypertension, open-angle glaucoma | Allergan | Completed | No outcome recorded |
| Phase 216 trials | ||||||
| Phase 2 | NCT06122090 | Jul 2023 → Dec 2024 | hypopigmentation of the skin, reactive cutaneous fibrous lesion | Medstar Health Research Institute | Unknown | No outcome recorded |
| Phase 2 | NCT04747808 | Jan → Feb 2021 | ocular hypertension, open-angle glaucoma | MediPrint Ophthalmics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03419715 | Jan 2018 → Apr 2019 | migraine disorder | Manistee Partners | Unknown | No outcome recorded |
| Phase 2 | NCT03292796 | Dec 2016 → Oct 2019 | open-angle glaucoma | Julie Dawson | Completed | No outcome recorded |
| Phase 2 | NCT02537015 | Aug 2015 → Aug 2016 | ocular hypertension, open-angle glaucoma | ForSight Vision5, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02358369 | Jan → Aug 2015 | ocular hypertension, open-angle glaucoma | ForSight Vision5, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02143843 | Jun 2014 → Dec 2015 | ocular hypertension, open-angle glaucoma | ForSight Vision5, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01915940 | Oct 2013 → Sep 2014 | ocular hypertension, open-angle glaucoma | ForSight Vision5, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01904721 | Aug 2013 → Sep 2014 | androgenetic alopecia | Allergan | Completed | No outcome recorded |
| Phase 2 | NCT01325350 | Jun 2011 → Jul 2012 | androgenetic alopecia | Allergan | Completed | No outcome recorded |
| Phase 2 | NCT01325337 | Jun 2011 → Aug 2012 | baldness, male pattern | Allergan | Completed | No outcome recorded |
| Phase 2 | NCT01291108 | Apr → Oct 2011 | ocular hypertension, open-angle glaucoma | Allergan | Completed | No outcome recorded |
| Phase 2 | NCT01064882 | Mar → Jul 2010 | hypotrichosis of eyelid | Allergan | Completed | No outcome recorded |
| Phase 2 | NCT00538304 | Nov 2007 → May 2008 | glaucoma, ocular hypertension | Allergan | Completed | No outcome recorded |
| Phase 2 | NCT00652496 | Jan → May 2005 | glaucoma, ocular hypertension | Allergan | Completed | No outcome recorded |
| Phase 2 | NCT00651859 | Nov 2002 → Jan 2004 | glaucoma, ocular hypertension | Allergan | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00300443 | Dec 2005 → Jun 2007 | ocular hypertension | Allergan | Completed | No outcome recorded |
| Phase 332 trials | ||||||
| Phase 3 | NCT07661329 | Jun 2026 → Nov 2027 expected | ocular hypertension, open-angle glaucoma | YS Life Science Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07218796 | Oct 2025 → May 2029 expected | cataract, glaucoma, ocular hypertension | SpyGlass Pharma, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT07218783 | Oct 2025 → Mar 2029 expected | cataract, ocular hypertension, open-angle glaucoma | SpyGlass Pharma, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT05397600 | Jun 2022 → Mar 2024 | glaucoma, ocular hypertension | Laboratoires Thea | Completed | No outcome recorded |
| Phase 3 | NCT04898387 | Mar 2021 → Apr 2023 | ocular hypertension | Laboratoires Thea | Completed | No outcome recorded |
| Phase 3 | NCT04285580 | Jun 2020 → May 2022 | ocular hypertension, open-angle glaucoma | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT03891446 | Mar 2019 → Jun 2026 | ocular hypertension, open-angle glaucoma | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT03850782 | Feb 2019 → Aug 2025 | ocular hypertension, open-angle glaucoma | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT03825380 | Nov 2018 → Feb 2021 | glaucoma, ocular hypertension | Laboratoires Thea | Completed | No outcome recorded |
| Phase 3 | NCT02636946 | Feb 2016 → Jan 2021 | glaucoma, ocular hypertension | Allergan | Completed | No outcome recorded |
| Phase 3 | NCT02390284 | Sep 2015 → Oct 2024 | glaucoma | University of Miami | Terminated | No outcome recorded |
| Phase 3 | NCT02507687 | Aug 2015 → Nov 2021 | ocular hypertension, open-angle glaucoma | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT02250651 | Dec 2014 → Oct 2018 | ocular hypertension, open-angle glaucoma | Allergan | Completed | No outcome recorded |
| Phase 3 | NCT02155049 | Nov 2014 → May 2017 | disease of orbital part of eye adnexa | Rabin Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT01830140 | Jul 2013 → May 2014 | glaucoma, ocular hypertension | Allergan | Completed | No outcome recorded |
| Phase 3 | NCT01765764 | Mar 2013 → Jan 2014 | hypotrichosis | Allergan | Completed | No outcome recorded |
| Phase 3 | NCT01698554 | Nov 2012 → Feb 2014 | hypotrichosis of eyelid | Allergan | Completed | No outcome recorded |
| Phase 3 | NCT01426113 | Sep 2011 → Oct 2014 | glaucoma | Allergan | Terminated | No outcome recorded |
| Phase 3 | NCT01391273 | Jul 2011 → May 2012 | hypotrichosis of eyelid | Allergan | Completed | No outcome recorded |
| Phase 3 | NCT01391286 | Jul 2011 → May 2012 | hypotrichosis of eyelid | Allergan | Completed | No outcome recorded |
| Phase 3 | NCT01241240 | Mar 2011 → Sep 2013 | ocular hypertension, open-angle glaucoma | Allergan | Completed | No outcome recorded |
| Phase 3 | NCT01217606 | Jan 2011 → Sep 2014 | ocular hypertension, open-angle glaucoma | Allergan | Completed | No outcome recorded |
| Phase 3 | NCT01216943 | Nov 2010 → Aug 2012 | glaucoma, ocular hypertension | Allergan | Completed | No outcome recorded |
| Phase 3 | NCT01168414 | Aug 2010 → Jan 2011 | ocular hypertension, open-angle glaucoma | Ministry of Health, Malaysia | Completed | No outcome recorded |
| Phase 3 | NCT01099774 | May 2010 → Apr 2011 | glaucoma, ocular hypertension | Allergan | Completed | No outcome recorded |
| Phase 3 | NCT00907426 | Aug 2009 → Nov 2010 | hypotrichosis | Allergan | Completed | No outcome recorded |
| Phase 3 | NCT00693420 | Apr → Oct 2007 | — | Allergan | Completed | No outcome recorded |
| Phase 3 | NCT01200251 | Feb → Sep 2007 | alopecia, isolated, hypotrichosis | Duke University | Completed | No outcome recorded |
| Phase 3 | NCT00332059 | May 2003 → Sep 2004 | ocular hypertension | Allergan | Completed | No outcome recorded |
| Phase 3 | NCT00332072 | Aug 2001 → Aug 2003 | ocular hypertension | Allergan | Completed | No outcome recorded |
| Phase 3 | NCT00332540 | Aug 2001 → Aug 2003 | ocular hypertension | Allergan | Completed | No outcome recorded |
| Phase 3 | NCT02154217 | ? → Dec 2004 | glaucoma | University of Milan | Completed | No outcome recorded |
| Phase 435 trials | ||||||
| Phase 4 | NCT07217678 | Feb 2026 → Jan 2028 expected | borderline glaucoma, ocular hypertension, open-angle glaucoma | University of Miami | Recruiting | No outcome recorded |
| Phase 4 | NCT04981886 | Aug 2021 → Jul 2022 | low tension glaucoma | Salus University | Unknown | No outcome recorded |
| Phase 4 | NCT06761313 | Mar 2021 → Dec 2024 overdue | glaucoma | Federal University of São Paulo | Active not recruiting | No outcome recorded |
| Phase 4 | NCT03487042 | May 2018 → Dec 2019 | generalized vitiligo | Assiut University | Unknown | No outcome recorded |
| Phase 4 | NCT02863705 | Jul 2016 → Jul 2018 | low tension glaucoma | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT02571712 | Nov 2015 → Jun 2018 | ocular hypertension, open-angle glaucoma | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT02471105 | Sep 2015 → May 2017 | glaucoma, ocular hypertension | Universitaire Ziekenhuizen KU Leuven | Unknown | No outcome recorded |
| Phase 4 | NCT02176356 | Jun 2014 → May 2015 | — | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT01927406 | Jun 2014 → Dec 2016 | endocrine exophthalmos, glaucoma, ocular hypertension | Stanford University | Withdrawn | No outcome recorded |
| Phase 4 | NCT03966560 | Jan 2014 → Jan 2015 | open-angle glaucoma | Afyon Kocatepe University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01975714 | Oct 2013 → Feb 2015 | glaucoma, ocular hypertension | Association for Innovation and Biomedical Research on Light and Image | Completed | No outcome recorded |
| Phase 4 | NCT01891487 | May 2013 → Sep 2014 | hypotrichosis | ATS Clinical Research | Completed | No outcome recorded |
| Phase 4 | NCT01594970 | Mar 2012 → Jan 2013 | ocular hypertension, open-angle glaucoma | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT01535768 | Feb 2012 → Jun 2018 | glaucoma | Credit Valley EyeCare | Unknown | No outcome recorded |
| Phase 4 | NCT01978015 | Oct 2011 → Jul 2012 | anterior uveitis, cystoid macular edema | University of Campinas, Brazil | Completed | No outcome recorded |
| Phase 4 | NCT01464424 | Oct 2011 → Jun 2012 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT02020512 | Jul 2011 → Dec 2012 | ocular hypertension, open-angle glaucoma | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT01298700 | May 2011 → Dec 2016 | glaucoma, ocular hypertension | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT01387906 | Mar 2011 → Mar 2012 | hypotrichosis | Kenneth Beer | Completed | No outcome recorded |
| Phase 4 | NCT01271686 | Jan 2011 → Oct 2012 | glaucoma, ocular hypertension | University of California, San Diego | Completed | No outcome recorded |
| Phase 4 | NCT01202513 | Aug → Nov 2010 | vitiligo | Gian Sagar Medical College and Hospital | Withdrawn | No outcome recorded |
| Phase 4 | NCT02061683 | Apr 2010 → Jun 2011 | ocular hypertension, open-angle glaucoma | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT01833741 | Dec 2009 → Mar 2011 | ocular hypertension, open-angle glaucoma | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT01229423 | Nov 2009 → Jun 2010 | hypotrichosis of eyelid | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT00958035 | Nov 2009 → Jul 2010 | hypotrichosis | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT00941096 | Jul 2009 → Nov 2010 | glaucoma, ocular hypertension | Larissa University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00539526 | Sep 2007 → Jul 2008 | ocular hypertension, open-angle glaucoma | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT00440011 | Aug 2006 → Oct 2007 | glaucoma, ocular hypertension | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT00273455 | Jan 2006 → May 2007 | open-angle glaucoma | Pharmaceutical Research Network | Completed | No outcome recorded |
| Phase 4 | NCT00329095 | Dec 2005 → Apr 2006 | glaucoma, ocular hypertension | Robin, Alan L., M.D. | Completed | No outcome recorded |
| Phase 4 | NCT00355446 | Jul 2001 → Oct 2004 | cataract | Indiana University | Completed | No outcome recorded |
| Phase 4 | NCT00347841 | — | glaucoma | Innovative Medical | Completed | No outcome recorded |
| Phase 4 | NCT00347802 | — | glaucoma | Innovative Medical | Completed | No outcome recorded |
| Phase 4 | NCT00348023 | — | glaucoma | Innovative Medical | Completed | No outcome recorded |
| Phase 4 | NCT00348062 | — | glaucoma | Innovative Medical | Completed | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT07154797 | Apr → Dec 2022 | cataract, glaucoma, ocular hypertension | SpyGlass Pharma, Inc. | Completed | No outcome recorded |
| — | NCT00999557 | Jan 2016 → Aug 2017 | alopecia, breast cancer | Jonsson Comprehensive Cancer Center | Withdrawn | No outcome recorded |
| — | NCT02448043 | Jun 2015 → May 2016 | ocular hypertension | Northwestern University | Completed | No outcome recorded |
| — | NCT01542710 | Jan → Dec 2011 | open-angle glaucoma | Kasr El Aini Hospital | Completed | No outcome recorded |
| — | NCT01361841 | Jan 2009 → Jan 2012 | ocular hypertension, open-angle glaucoma | Centre de recherche du Centre hospitalier universitaire de Sherbrooke | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 38 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00809848 Comparator | Feb → May 2009 | glaucoma, ocular hypertension | Allergan | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT05335122 Comparator | Mar 2022 → Jan 2024 | ocular hypertension, open-angle glaucoma | Ocular Therapeutix, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01863953 Comparator | Jun → Dec 2013 | glaucoma, ocular hypertension | Allergan | Completed | No outcome recorded |
| Phase 2 | NCT01110499 Comparator | Jun 2010 → May 2011 | ocular hypertension, open-angle glaucoma | Allergan | Completed | No outcome recorded |
| Phase 2 | NCT01001195 Comparator | Nov 2009 → Apr 2010 | ocular hypertension, open-angle glaucoma | Allergan | Completed | No outcome recorded |
| Phase 2 | NCT02170662 Comparator | Nov 2009 → May 2011 | baldness, male pattern | Duke University | Completed | No outcome recorded |
| Phase 2 | NCT01016691 Background | Oct 2009 → Feb 2010 | ocular hypertension, open-angle glaucoma | Vistakon Pharmaceuticals | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT03927443 Comparator | Jun → Jul 2019 | ocular hypertension, open-angle glaucoma | Sun Pharmaceutical Industries, Inc. | Withdrawn | No outcome recorded |
| Phase 3 | NCT03284853 Comparator | Sep 2017 → Nov 2020 | ocular hypertension, open-angle glaucoma | Aerie Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01177098 Comparator | Oct 2010 → Feb 2012 | glaucoma, ocular hypertension | Allergan | Completed | No outcome recorded |
| Phase 421 trials | ||||||
| Phase 4 | NCT06369077 Comparator | Apr → Jul 2024 | open-angle glaucoma | CT Glaucoma Associates | Terminated | No outcome recorded |
| Phase 4 | NCT02419508 Background | Aug 2015 → Feb 2018 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT02059655 Comparator | Nov 2014 → Mar 2016 | disease of orbital part of eye adnexa | Cardiff University | Completed | No outcome recorded |
| Phase 4 | NCT02097719 Comparator | May → Dec 2014 | glaucoma, ocular hypertension | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT02017327 Comparator | Dec 2013 → Jul 2016 | ocular hypertension, open-angle glaucoma | Laboratoires Thea | Completed | No outcome recorded |
| Phase 4 | NCT01937312 Background | Oct 2013 → May 2014 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT01881126 Comparator | Jun 2013 → Oct 2014 | glaucoma, ocular hypertension | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT01664039 Comparator | Sep 2012 → Jun 2014 | glaucoma, ocular hypertension | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT01525173 Comparator | Jan → Oct 2012 | glaucoma, ocular hypertension | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT01547598 Comparator | Dec 2011 → Jul 2013 | ocular hypertension, open-angle glaucoma | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT01448525 Comparator | Oct 2011 → Apr 2012 | hypotrichosis | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT01263444 Background | Mar 2011 → Apr 2013 | glaucoma, ocular hypertension | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT01253902 Comparator | Dec 2010 → Oct 2011 | ocular hypertension, open-angle glaucoma | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT01023841 Comparator | Jun 2010 → Nov 2012 | alopecia areata, hypotrichosis of eyelid | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT01243567 Comparator | Jun 2010 → Feb 2012 | open-angle glaucoma | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT01448837 Comparator | Apr 2010 → Mar 2011 | glaucoma | Aristotle University Of Thessaloniki | Completed | No outcome recorded |
| Phase 4 | NCT01170884 Comparator | Dec 2009 → Sep 2010 | glaucoma, ocular hypertension | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT00705757 Comparator | Mar 2008 → Apr 2011 | glaucoma, hyperpigmentation of the skin | Summa Health System | Completed | No outcome recorded |
| Phase 4 | NCT00541242 Comparator | Dec 2007 → Aug 2008 | glaucoma, ocular hypertension | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT01655758 Comparator | Jan 2002 → Dec 2003 | ocular hypertension | University of Parma | Completed | No outcome recorded |
| Phase 4 | NCT00847483 Comparator | Jan → Aug 2002 | glaucoma, ocular hypertension | Viatris Inc. | Completed | No outcome recorded |
| Phase not applicable6 trials | ||||||
| — | NCT05241938 Comparator | Sep 2021 → Dec 2022 | ocular hypertension, open-angle glaucoma | Federal University of Rio Grande do Sul | Unknown | No outcome recorded |
| — | NCT02774811 Comparator | Feb 2014 → Jan 2019 | glaucoma | University College, London | Terminated | No outcome recorded |
| — | NCT01068964 Comparator | Feb → Sep 2010 | ocular hypertension, open-angle glaucoma | Allergan | Completed | No outcome recorded |
| — | NCT00773136 Comparator | Feb → Jul 2008 | hypertrichosis | University of Miami | Completed | No outcome recorded |
| — | NCT00567788 Comparator | Jul 2006 → Jul 2008 | chronic closed-angle glaucoma | Singapore National Eye Centre | Unknown | No outcome recorded |
| — | NCT00187577 Comparator | Jun 2005 → Feb 2006 | alopecia areata | University of California, San Francisco | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT05338606 Background | — | open-angle glaucoma | AbbVie | No longer available | No outcome recorded |
Press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-02-25 | AbbVie | Allergan to Present New Data for Investigational Bimatoprost Sustained-Release at American Glaucoma Society Annual Meeting abbvie.com ↗ |
| 2019-07-17 | AbbVie | U.S. FDA Accepts Allergan's New Drug Application for Bimatoprost Sustained-Release in Patients with Open-Angle Glaucoma or Ocular Hypertension abbvie.com ↗ |
| 2019-05-03 | AbbVie | Allergan to Present Two Podium Presentations on Bimatoprost Sustained-Release (SR) at The American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting abbvie.com ↗ |
| 2019-03-14 | AbbVie | Allergan to Present New Data - "Extended Duration of Intraocular Pressure (IOP) Control with Intracameral Bimatoprost Sustained-Release (SR) Implant" -- Highlighting Clinical Advances at the American Glaucoma Society Annual Meeting abbvie.com ↗ |
| 2019-01-07 | AbbVie | Allergan Announces Positive 3-Month Topline Results from Second Phase 3 Study of Bimatoprost SR (Sustained-Release) Implant for Lowering Intraocular Pressure (IOP) in Patients with Open-Angle Glaucoma or Ocular Hypertension abbvie.com ↗ |
| 2018-06-13 | AbbVie | Allergan Announces Positive Topline Phase 3 Clinical Data for Bimatoprost SR (Sustained-Release) Implant for IOP Lowering in Patients with Open-Angle Glaucoma or Ocular Hypertension abbvie.com ↗ |
Evidence & citations 26 cited values
Every value below carries the sentence it was read from. 143 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bimatoprost | “a topical prostaglandin analogue eye drop. (latanoprost 0.005% 1 gtts in study eye qhs OR travoprost 0.004% 1 gtts in study eye qhs OR bimatoprost 0.01% 1 gtts in study eye qhs...” NCT01535768 ↗137“prostaglandin analog eyedrop (bimatoprost 0.01%, travoprost z 0.004%, tafluprost 0.0015% or latanoprost 0.005%) will be administered once a day, topically, into one - randomised eye.” NCT01927406 ↗ “Fixed combination of Bimatoprost and Timolol (BTFC; Ganfort (300 microgram + 5 mg/ml eyedrops solution)” NCT01168414 ↗ “GANFORT® (bimatoprost 0.03%/timolol 0.5%) Ophthalmic solution one drop daily to each eye for 180 days.” NCT03284853 ↗ “Prostaglandin analogue eye drops (latanoprost, bimatoprost or travoprost) will be prescribed” NCT05241938 ↗ “Lumigan® 0.01%: Bimatoprost eye drop solution is supplied in 3 ml multidose container.” NCT02017327 ↗ “Compare also to timolol/brimonidine/dorzolamide/bimatoprost” NCT06369077 ↗ “Group 4 extended-wear contact lens printed with bimatoprost” NCT04747808 ↗ “Lumigan ® 0.01% (Bimatoprost Ophthalmic Solution)” NCT03927443 ↗ “LUMIGAN® (Bimatoprost ophthalmic solution, 0.01%)” NCT02419508 ↗ “Bimatoprost 0.03% solution applied to eyebrow” NCT01891487 ↗ “Latanoprost Travaprost Bimatoprost Tafluprost” NCT03292796 ↗ “Bimatoprost-Drug Ring System Low Dose” NCT07641296 ↗ “Bimatoprost Ocular Insert” NCT02742649 ↗ “Bimatoprost” NCT02774811 ↗ “Bimatoprost” NCT01263444 ↗ |
| Known as | "Lumigan" is the branded name of bimatoprost in eye drop form | “"Lumigan" is the branded name of bimatoprost in eye drop form” NCT02537015 ↗1“"Lumigan" is the branded name of bimatoprost in eye drop form” NCT02143843 ↗ |
| Known as | AGN 192024 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200963 ↗ |
| Known as | BIM | “BAK-free travoprost 0.004% (TRAV) and BAK 0.02%-preserved bimatoprost 0.01% (BIM) during late-day time points in patients with open-angle glaucoma or ocular hypertension.” PMID 25432143 ↗ Nov 2014 |
| Known as | Bimatoprost 0.03% solution (Lumigan) | “Bimatoprost 0.03% solution (Lumigan)” NCT00187577 ↗ |
| Known as | Bimatoprost component of ganfort | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200963 ↗ |
| Known as | Bimatoprost Implant System | “Bimatoprost Implant System (High Dose) used in combination with the SpyGlass IOL” NCT06120842 ↗ |
| Known as | Bimatoprost SR | “Bimatoprost SR is a biodegradable, sustained-release, preservative-free bimatoprost implant, preloaded in an applicator for administration.” NCT02507687 ↗1“received commercial DURYSTA (Bimatoprost SR) in the open-label Phase 4 ARGOS study” NCT03891446 ↗ |
| Known as | bimatoprost sustained-release (SR) | “This study will evaluate the efficacy and safety of bimatoprost sustained-release (SR) in patients with open-angle glaucoma or ocular hypertension.” NCT02250651 ↗ |
| Known as | BUDPF | “After the follow-up visit, patient will start Preservative-free bimatoprost 0.03% Unit Dose (BUDPF) eye drops every day at 21:00 for the last 3 months.” NCT01975714 ↗ |
| Known as | Durysta | “Participants in this arm will receive a one-time injection of Durysta (intracameral bimatoprost 10mcg).” NCT07217678 ↗1“Durysta, Bimatoprost Intracameral Implant 10 µg” NCT05335122 ↗ |
| Known as | DurystaTM | “Currently, Bimatoprost SR (DurystaTM) from Allergan plc is the only FDA-approved SR therapy for POAG.” PMID 35076329 ↗ Dec 2022 |
| Known as | Ganfort | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01542710 ↗ |
| Known as | Latisse | “Bimatoprost 0.03% ophthalmic solution is currently approved by the FDA for treatment of glaucoma (Lumigan™) and for thickening of thin eyelashes (Latisse™).” NCT02170662 ↗ |
| Known as | Lumigan | “Bimatoprost ophthalmic solution 0.01% (LUMIGAN®) administered once daily in the evening 5 minutes after COMBIGAN® instillation if additional lowering IOP is needed” NCT02863705 ↗9“Bimatoprost 0.03% ophthalmic solution is currently approved by the FDA for treatment of glaucoma (Lumigan™) and for thickening of thin eyelashes (Latisse™).” NCT02170662 ↗ “dosed with TRAVATAN Z®, XALATAN®, or LUMIGAN®, 1 drop instilled in each eye once daily for 28 days” NCT01937312 ↗ “bimatoprost ophthalmic solution 0.03% (LUMIGAN®) in both eyes once daily for 4 weeks.” NCT01110499 ↗ “Lumigan/bimatoprost 0.03% ophthalmic solution one drop qhs for one year” NCT00705757 ↗ “Bimatoprost, aka Lumigan, one drop in one eye nightly” NCT03708627 ↗ “Bimatoprost (Lumigan) ophthalmic solution” NCT00187577 ↗ “bimatoprost = Lumigan®” NCT00541242 ↗ |
| Known as | LUMIGAN (Bimatoprost ophthalmic solution, 0.01%) | “LUMIGAN® (Bimatoprost ophthalmic solution, 0.01%)” NCT02419508 ↗ |
| Known as | Lumigan 0.01% | “Lumigan® 0.01%: Bimatoprost eye drop solution is supplied in 3 ml multidose container.” NCT02017327 ↗ |
| Known as | Lumigan 0.03% Unit Dose | “Lumigan® 0.03% Unit Dose: Bimatoprost eye drop solution is supplied in 0.4 ml single use low density polyethylene (LDPE) containers.” NCT02017327 ↗ |
| Known as | LUMIGAN RC | “Bimatoprost 0.01% (LUMIGAN® RC) administered as one drop in the study eye(s) each evening for 12 weeks.” NCT01833741 ↗ |
| Known as | Lumigan TM | “Three of these are commonly used in North America: latanoprost (Latanoprost T, Pfizer), Travoprost (Travatan TM, Alcon) and bimatoprost (Lumigan TM, Allergan).” NCT01361841 ↗ |
| Known as | Prostamide | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200963 ↗ |
| Known as | T4032 | “Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients” NCT05397600 ↗1“Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy Volunteers” NCT05729594 ↗ |
| Action | Activate | “Prostanoid FP receptor agonist” CHEMBL1200963 ↗ |
| Modality | Other / unclassified | “prostaglandin analogues bimatoprost ophthalmic solution 0.01% (Lumigan® 0.01%), travoprost ophthalmic solution 0.004% (Travatan Z®) and latanoprost ophthalmic solution 0.005% (Xalatan®)” NCT01253902 ↗ |
| Route | Topical | “Bimatoprost solution will be applied to affected eyelid(s) with cotton-tipped applicator daily.” NCT00187577 ↗ |
| Target | PTGFR | “Prostanoid FP receptor agonist” CHEMBL1200963 ↗ |